Shanghai Fosun Pharmaceutical (Group) Co., Ltd.SSE: 600196

Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial

· Issued by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that its subsidiary has received approval for a clinical trial of a new drug.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Holding Subsidiary’s Drug Obtaining Approval for Clinical Trial

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on 6ix

Earlier from Shanghai Fosun Pharmaceutical (Group)

Later from Shanghai Fosun Pharmaceutical (Group)

All Shanghai Fosun Pharmaceutical (Group) news releases